
Expectation is that the president will issue an executive order transferring the plant to Schedule III; measure would facilitate research and banking access after cannabis reclassification

In Canada, cannabis producers are adopting transparent packaging to increase consumer confidence, differentiate themselves from the conventional industry, and reinforce product quality

Proposal aims to change rules to allow reimbursement of hemp-derived products in health plans for seniors starting in 2027

New partnerships with insurers and healthcare systems aim to facilitate clinically oriented treatments for millions of Americans

Amid tensions with Trump, Gustavo Petro suggests drug policy change and cannabis exports

New legislation redefines hemp and prohibits most broad-spectrum CBD products starting in 2026

U.S. President says he is considering the reclassification of cannabis, a measure that could impact research, the market, and federal cannabis policy

See which states in the United States may advance in cannabis legalization in 2026, with legislative initiatives and possible popular votes under discussion

Ayr Wellness' restructuring plan exposes financial fragility of cannabis operators in the United States

Proposal presented by Republican senators seeks to block the use of federal resources to reclassify cannabis in the United States

Legal action in the United States involves former executives and companies responsible for licensing and managing celebrity-associated cannabis brands

Research conducted by a United States university observed cognitive improvement and reduction of disease markers in animal models from the combination of THC and an anti-inflammatory medication

Survey conducted with adults in the United States shows majority in favor of legalizing recreational cannabis use and broad recognition of its medicinal use

The possible reclassification of cannabis in the United States could expand access to credit, advertising, and ease tax burdens, opening up new opportunities for companies in the sector

Survey indicates that 3.7% of the adult population in the United States reported using subperceptual doses of psychedelics in the last year

The DEA has increased the legal quotas for the production of psychedelics such as psilocybin and DMT for 2026, focusing on scientific and medical research in the United States

The longest strike in the United States cannabis industry came to an end after 45 days, with victory for Green Thumb Industries workers

Category grows 12% annually and already represents 15.4% of the total cannabis market in the United States

Business of Cannabis: New York 2025 will bring together investors, regulators, and industry leaders to discuss the future of cannabis in the United States, focusing on innovation, sustainability, and regulation

In a press conference, the Venezuelan president states that the country will not follow the "insane trend" of legalizing drugs and points to the production of "synthetic super marijuana" in the United States